OQROSign up free
Politician trade (House)

Merck (MRK): Rep. Jefferson Shreve (IN06) disclosed a sale $15K–$50K

Rep. Jefferson Shreve (IN06) disclosed a sale of Merck in the $15K–$50K range.

$15,001–$50,000
Reported range · official band, not an exact amount
21 days
Disclosure lag
Traded
Apr 17, 2025
Disclosed
May 8, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 7, 2024CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  2. Feb 19, 2025InsiderOfficer sold ~$715K of MRK shares in the open market
  3. Feb 24, 2025CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
  4. Feb 25, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
  5. Feb 26, 2025CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
  6. Mar 3, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  7. Mar 19, 2025FDAFDA drug approval: Keytruda
  8. Mar 20, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
  9. Mar 31, 2025CongressDisclosed partial sale of MRK — reported range $15,001 - $50,000
  10. Apr 8, 2025CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
  11. Apr 9, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  12. Apr 15, 2025FDAFDA drug approval: Welireg
  13. Apr 15, 2025FDAFDA drug approval: Welireg
  14. Apr 17, 2025 · this disclosureCongressDisclosed sale of MRK — reported range $15,001 - $50,000

What came next

  1. Apr 21, 2025FDAFDA drug approval: Keytruda
  2. Apr 21, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  3. Apr 25, 2025InsiderOfficer sold ~$353K of MRK shares in the open market
  4. Apr 29, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  5. May 5, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  6. May 14, 2025FDAFDA drug approval: Welireg
  7. May 15, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
  8. May 22, 2025FDAFDA drug approval: Keytruda
  9. May 30, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  10. Jun 3, 2025FDAFDA drug approval: Keytruda
  11. Jun 6, 2025FDAFDA drug approval: Keytruda
  12. Jun 9, 2025FDAFDA drug approval: Enflonsia
  13. Jun 12, 2025FDAFDA drug approval: Keytruda
  14. Jun 13, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  15. Jun 16, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  16. Jun 24, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  17. Jul 21, 2025FDARecall: Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card contains 10 Tablets, Rx only, Merck Sharp & Dohme LLC, Rahway,…
  18. Jul 24, 2025FDAFDA drug approval: Keytruda
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Merck

For Merck, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 4 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

Other recent filings by Rep. Jefferson Shreve (IN06)

The full history of Rep. Jefferson Shreve (IN06) is on the profile page.

How this filing works

Explore the data

Other disclosures at Merck

Everything OQRO holds on this company is on its MRK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data